1092952-98-1

Basic information

• Product Name: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate
• CAS NO: 1092952-98-1
• Molecular Weight: 424.293
• Mol File: 1092952-98-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(1092952-98-1)
• EPA Substance Registry System: ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate(1092952-98-1)

Safety Data

• Hazardous Substances Data: 1092952-98-1(Hazardous Substances Data)

Usage

General Description

Ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate is a chemical compound with a complex structure. It contains an ethyl ester group, a dihydropyrimidine ring, and various substituents including bromine, fluorine, and thiazole. ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate may have potential pharmacological properties due to its structural features, and it could be studied for its potential use as a pharmaceutical agent. However, further research and testing would be required to fully understand its properties and potential applications.

Upstream product

• 247037-82-7 1,3-thiazole-2-carboximidamide hydrochloride 
• 59142-68-6 2-bromo-4-fluorobenzaldehyde 
• 141-97-9 ethyl acetoacetate 
• 64-17-5 ethanol 

Downstream Products

• 1092953-04-2 ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate 
• 1092970-12-1 ethyl (R,S)-6-(2-bromo-4-fluorophenyl)-4-(morpholinomethyl)-2-(thiazol-2-yl)-1,6-dihydropyrimidine-5-carboxylate 

Relevant articles and documents

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

Dihydropyrimidine-spiro derivative as well as preparation method and application thereof

The invention provides a dihydropyrimidine-spiro derivative as well as a preparation method and application thereof. The compound has a structure as shown in a formula I. The invention further relates to a preparation method of the compound with the structure shown in the formula I, a pharmaceutical composition and application of the compound in preparation of anti-HBV drugs.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.